Pfizer Inc. (NYSE:PFE) Shares Purchased by LGT Group Foundation

Key Points

• LGT Group Foundation increased its stake in Pfizer Inc. by 67.3% in the first quarter, acquiring an additional 616,655 shares for a total worth of $38.86 million.
• Pfe's latest earnings report showed an EPS of $0.78, surpassing estimates of $0.58, with a revenue of $14.65 billion, which is a 10.3% increase from the previous year.
• The company has declared a quarterly dividend of $0.43, resulting in a 7.0% dividend yield and a payout ratio of 91.49%.

LGT Group Foundation increased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 67.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,533,401 shares of the biopharmaceutical company's stock after purchasing an additional 616,655 shares during the period. LGT Group Foundation's holdings in Pfizer were worth $38,856,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. William B. Walkup & Associates Inc. raised its holdings in Pfizer by 1.2% in the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after acquiring an additional 454 shares during the last quarter. Members Trust Co increased its holdings in shares of Pfizer by 2.1% during the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after buying an additional 467 shares during the last quarter. Sutton Place Investors LLC increased its holdings in shares of Pfizer by 5.6% during the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock worth $224,000 after buying an additional 472 shares during the last quarter. Bellevue Group AG increased its holdings in shares of Pfizer by 0.3% during the 4th quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company's stock worth $3,756,000 after buying an additional 485 shares during the last quarter. Finally, Trust Asset Management LLC increased its holdings in shares of Pfizer by 0.8% during the 1st quarter. Trust Asset Management LLC now owns 65,183 shares of the biopharmaceutical company's stock worth $1,652,000 after buying an additional 490 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research analyst reports. Redburn Atlantic dropped their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a report on Wednesday, April 30th. HSBC decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. TD Cowen decreased their price objective on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research report on Tuesday, April 22nd. Finally, BMO Capital Markets decreased their price objective on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $28.12.

Pfizer Stock Performance

Shares of NYSE PFE opened at $24.61 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm's 50-day moving average price is $24.46 and its two-hundred day moving average price is $24.47. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The stock has a market capitalization of $139.93 billion, a P/E ratio of 13.09, a P/E/G ratio of 0.88 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the business earned $0.60 earnings per share. Pfizer's revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer's dividend payout ratio (DPR) is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.